CALL - SPRINTER OPEN END - BIOGEN IDEC | Delayed Deutsche Boerse AG 07:43:47 2024-05-23 EDT | ||
| 5.55 EUR | -4.48% |
|
| Current month | +15.51% | ||
| 1 month | +90.49% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
BIOGEN INC.
Latest news about BIOGEN INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-05-23 | 5.55 | -4.48% |
| 24-05-22 | 5.81 | 0.00% |
| 24-05-21 | 5.81 | -8.65% |
| 24-05-20 | 6.36 | +4.61% |
| 24-05-17 | 6.08 | -0.65% |
Delayed Quote Deutsche Boerse AG
Last update May 23, 2024 at 07:43 am
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | BIOGEN INC. |
| Issuer | 
Vontobel
|
| WKN | VV3XT2 |
| ISIN | DE000VV3XT20 |
| Date issued | 2022-06-17 |
| Strike | 165.6 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 5.03 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 16.13 € |
|---|---|
| Lowest since issue | 2.55 € |
| Spread | 0.11 € |
| Spread % | 1.93% |
Company Profile
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows:
- sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.;
- royalties (17,2%) ;
- other (9,1%): primarily revenues from partnership agreements.
Sector
-
Consensus: Biogen Inc.
Sell
Buy
Mean consensus
BUY
Number of Analysts
33
Last Close Price
225.2
USD
Average target price
287.3
USD
Spread / Average Target
+27.57%
- Stock Market
- Certificates
- Certificat
